-mab
A monoclonal antibody: a lab-made antibody aimed at one target. WHO used -mab until 2021, with syllables in front naming the target and, until 2017, the species the antibody came from.
- Drugs ending in -mab: 758
- Approved somewhere: 150
- With a US drug page: 134
- Stem
- -mab
- Class
- Monoclonal antibodies named under the pre-2021 scheme
- Sub-stems
- -vetmab
Approved and clinical-stage drugs in ChEMBL whose names ending in -mab or one of its sub-stems, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Abciximab | Approved | ITGA2B, ITGB3, ITGAV, ITGB3 | Integrin alpha-IIb/beta-3 inhibitor |
| Aducanumab | Approved | APP | Amyloid-beta A4 protein binding agent |
| Alemtuzumab | Approved | CD52 | CAMPATH-1 antigen inhibitor |
| Alirocumab | Approved | PCSK9 | Subtilisin/kexin type 9 inhibitor |
| Amivantamab | Approved | EGFR, MET | Epidermal growth factor receptor erbB1 inhibitor |
| Anifrolumab | Approved | IFNAR1 | Interferon-alpha/beta receptor alpha chain antagonist |
| Ansuvimab | Approved | GP | Envelope glycoprotein binding agent |
| Atezolizumab | Approved | CD274 | Programmed cell death 1 ligand 1 inhibitor |
| Avelumab | Approved | CD274 | Programmed cell death 1 ligand 1 other |
| Basiliximab | Approved | Interleukin-2 receptor | Interleukin-2 receptor inhibitor |
| Belantamab mafodotin | Approved | TNFRSF17, Tubulin | Tumor necrosis factor receptor superfamily member 17 binding agent |
| Belimumab | Approved | TNFSF13B | Tumor necrosis factor ligand superfamily member 13B inhibitor |
| Benralizumab | Approved | IL5RA | Interleukin-5 receptor subunit alpha inhibitor |
| Bezlotoxumab | Approved | TCDB | Toxin B inhibitor |
| Bimekizumab | Approved | IL17A, IL17F | Interleukin 17A inhibitor |
| Blinatumomab | Approved | T cell surface glycoprotein CD3, CD19 | T cell surface glycoprotein CD3 cross-linking agent |
| Brentuximab vedotin | Approved | Tubulin, TNFRSF8 | Tubulin inhibitor |
| Brodalumab | Approved | IL17RA | Interleukin-17 receptor A antagonist |
| Brolucizumab | Approved | VEGFA | Vascular endothelial growth factor A inhibitor |
| Burosumab | Approved | FGF23 | Fibroblast growth factor 23 inhibitor |
| Canakinumab | Approved | IL1B | Interleukin-1 beta inhibitor |
| Caplacizumab | Approved | VWF | von Willebrand factor inhibitor |
| Cemiplimab | Approved | PDCD1 | Programmed cell death protein 1 inhibitor |
| Certolizumab pegol | Approved | TNF | TNF-alpha inhibitor |
| Cetuximab | Approved | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Cosibelimab | Approved | CD274 | Programmed cell death 1 ligand 1 inhibitor |
| Crizanlizumab | Approved | SELP | P-selectin blocker |
| Crovalimab | Approved | C5 | Complement C5 inhibitor |
| Daclizumab | Approved | Interleukin-2 receptor | Interleukin-2 receptor inhibitor |
| Daratumumab | Approved | CD38 | Lymphocyte differentiation antigen CD38 inhibitor |
| Dinutuximab | Approved | Disialoganglioside GD2 | Disialoganglioside GD2 binding agent |
| Donanemab | Approved | APP | Amyloid-beta A4 protein disrupting agent |
| Dostarlimab | Approved | PDCD1 | Programmed cell death protein 1 antagonist |
| Dupilumab | Approved | IL4R | Interleukin-4 receptor subunit alpha antagonist |
| Durvalumab | Approved | CD274 | Programmed cell death 1 ligand 1 inhibitor |
| Elotuzumab | Approved | SLAMF7 | SLAM family member 7 inhibitor |
| Elranatamab | Approved | T cell surface glycoprotein CD3, TNFRSF17 | T cell surface glycoprotein CD3 binding agent |
| Emapalumab | Approved | IFNG | Interferon gamma inhibitor |
| Emicizumab | Approved | F10, F9 | Coagulation factor IX and X other |
| Enfortumab vedotin | Approved | NECTIN4, Tubulin | Nectin-4 binding agent |
| Epcoritamab | Approved | MS4A1, T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20 binding agent |
| Eptinezumab | Approved | CALCA, CALCB | Calcitonin gene-related peptide inhibitor |
| Erenumab | Approved | CALCRL | Calcitonin gene-related peptide type 1 receptor antagonist |
| Evinacumab | Approved | ANGPTL3 | Angiopoietin-related protein 3 inhibitor |
| Evolocumab | Approved | PCSK9 | Subtilisin/kexin type 9 inhibitor |
| Faricimab | Approved | ANGPT2, VEGFA | Angiopoietin-2 inhibitor |
| Fremanezumab | Approved | CALCA, CALCB | Calcitonin gene-related peptide antagonist |
| Galcanezumab | Approved | CALCA, CALCB | Calcitonin gene-related peptide inhibitor |
| Gemtuzumab ozogamicin | Approved | CD33, DNA | Myeloid cell surface antigen CD33 binding agent |
| Glofitamab | Approved | MS4A1, T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20 binding agent |
| Guselkumab | Approved | IL12B, IL23A | Interleukin-23 inhibitor |
| Ibalizumab | Approved | CD4 | T-cell surface antigen CD4 inhibitor |
| Idarucizumab | Approved | Dabigatran | Dabigatran sequestering agent |
| Inebilizumab | Approved | CD19 | B-lymphocyte antigen CD19 binding agent |
| Inotuzumab ozogamicin | Approved | CD22, DNA | CD22 binding agent |
| Ipilimumab | Approved | CTLA4 | Cytotoxic T-lymphocyte protein 4 inhibitor |
| Isatuximab | Approved | CD38 | Lymphocyte differentiation antigen CD38 inhibitor |
| Ixekizumab | Approved | IL17A | Interleukin 17A inhibitor |
| Lanadelumab | Approved | KLKB1 | Plasma kallikrein inhibitor |
| Lebrikizumab | Approved | IL13 | Interleukin-13 inhibitor |
| Lecanemab | Approved | APP | Amyloid-beta A4 protein inhibitor |
| Loncastuximab tesirine | Approved | CD19, DNA | B-lymphocyte antigen CD19 binding agent |
| Margetuximab | Approved | ERBB2 | Receptor protein-tyrosine kinase erbB-2 inhibitor |
| Marstacimab | Approved | TFPI | Tissue factor pathway inhibitor inhibitor |
| Mepolizumab | Approved | IL5 | Interleukin-5 inhibitor |
| Mirikizumab | Approved | IL12B, IL23A | Interleukin-23 inhibitor |
| Mirvetuximab soravtansine | Approved | FOLR1, Tubulin | Folate receptor alpha binding agent |
| Mogamulizumab | Approved | CCR4 | C-C chemokine receptor type 4 cross-linking agent |
| Mosunetuzumab | Approved | T cell surface glycoprotein CD3, MS4A1 | T cell surface glycoprotein CD3 binding agent |
| Moxetumomab pasudotox | Approved | CD22, EEF2 | CD22 binding agent |
| Naxitamab | Approved | Disialoganglioside GD2 | Disialoganglioside GD2 binding agent |
| Necitumumab | Approved | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Nemolizumab | Approved | IL31RA | Interleukin-31 receptor subunit alpha inhibitor |
| Nirsevimab | Approved | F | Fusion glycoprotein F0 inhibitor |
| Nivolumab | Approved | PDCD1 | Programmed cell death protein 1 inhibitor |
| Obiltoxaximab | Approved | PAGA | Protective antigen binding agent |
| Obinutuzumab | Approved | MS4A1 | B-lymphocyte antigen CD20 binding agent |
| Ocrelizumab | Approved | MS4A1 | B-lymphocyte antigen CD20 binding agent |
| Ofatumumab | Approved | MS4A1 | B-lymphocyte antigen CD20 binding agent |
| Olaratumab | Approved | PDGFRA | Platelet-derived growth factor receptor alpha antagonist |
| Palivizumab | Approved | F | Fusion glycoprotein F0 inhibitor |
| Panitumumab | Approved | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Pembrolizumab | Approved | PDCD1 | Programmed cell death protein 1 inhibitor |
| Polatuzumab vedotin | Approved | CD79B, Tubulin | B-cell antigen receptor complex-associated protein beta chain binding agent |
| Pozelimab | Approved | C5 | Complement C5 inhibitor |
| Ramucirumab | Approved | KDR | Vascular endothelial growth factor receptor 2 inhibitor |
| Ravulizumab | Approved | C5 | Complement C5 inhibitor |
| Raxibacumab | Approved | PAGA | Protective antigen binding agent |
| Reslizumab | Approved | IL5 | Interleukin-5 inhibitor |
| Retifanlimab | Approved | PDCD1 | Programmed cell death protein 1 antagonist |
| Risankizumab | Approved | IL12B, IL23A | Interleukin-23 inhibitor |
| Romosozumab | Approved | SOST | Sclerostin inhibitor |
| Rozanolixizumab | Approved | FCGRT | IgG receptor FcRn large subunit p51 inhibitor |
| Sacituzumab govitecan | Approved | TACSTD2, TOP1 | Tumor-associated calcium signal transducer 2 binding agent |
| Sarilumab | Approved | IL6R | Interleukin-6 receptor alpha subunit antagonist |
| Satralizumab | Approved | IL6R, IL6ST | IL6Ralpha/GP130 antagonist |
| Secukinumab | Approved | IL17A | Interleukin 17A inhibitor |
| Siltuximab | Approved | IL6 | Interleukin-6 antagonist |
| Spesolimab | Approved | IL1RAP, IL1RL2 | IL36 receptor antagonist |
| Sutimlimab | Approved | C1S | Complement C1s inhibitor |
| Tafasitamab | Approved | CD19 | B-lymphocyte antigen CD19 binding agent |
| Talquetamab | Approved | T cell surface glycoprotein CD3, GPRC5D | T cell surface glycoprotein CD3 binding agent |
| Tarlatamab | Approved | T cell surface glycoprotein CD3, DLL3 | T cell surface glycoprotein CD3 binding agent |
| Teclistamab | Approved | T cell surface glycoprotein CD3, TNFRSF17 | T cell surface glycoprotein CD3 binding agent |
| Teplizumab | Approved | CD3E | T-cell surface glycoprotein CD3 epsilon chain other |
| Teprotumumab | Approved | IGF1R | Insulin-like growth factor I receptor antagonist |
| Tezepelumab | Approved | TSLP | Thymic stromal lymphopoietin inhibitor |
| Tildrakizumab | Approved | IL12B, IL23A | Interleukin-23 inhibitor |
| Tislelizumab | Approved | PDCD1 | Programmed cell death protein 1 inhibitor |
| Tisotumab vedotin | Approved | Tubulin, F3 | Tubulin inhibitor |
| Toripalimab | Approved | PDCD1 | Programmed cell death protein 1 antagonist |
| Tralokinumab | Approved | IL13 | Interleukin-13 inhibitor |
| Tremelimumab | Approved | CTLA4 | Cytotoxic T-lymphocyte protein 4 inhibitor |
| Ublituximab | Approved | MS4A1 | B-lymphocyte antigen CD20 binding agent |
| Vedolizumab | Approved | ITGA4, ITGB7 | Integrin alpha-4/beta-7 inhibitor |
| Zanidatamab | Approved | ERBB2 | Receptor protein-tyrosine kinase erbB-2 inhibitor |
| Zenocutuzumab | Approved | ERBB2, ERBB3 | ErbB-2/ErbB-3 heterodimer inhibitor |
| Zolbetuximab | Approved | CLDN18 | Claudin-18 binding agent |
| Apitegromab | Phase 3 | MSTN | Growth/differentiation factor 8 inhibitor |
| Clesrovimab | Phase 3 | F | Fusion glycoprotein F0 inhibitor |
| Datopotamab deruxtecan | Phase 3 | TACSTD2, TOP1 | Tumor-associated calcium signal transducer 2 binding agent |
| Depemokimab | Phase 3 | IL5 | Interleukin-5 inhibitor |
| Garetosmab | Phase 3 | INHBA | Inhibin beta A chain inhibitor |
| Ibritumomab tiuxetan | Phase 3 | — | — |
| Linvoseltamab | Phase 3 | — | — |
| Narsoplimab | Phase 3 | MASP2 | Mannan-binding lectin serine protease 2 inhibitor |
| Nipocalimab | Phase 3 | FCGRT | IgG receptor FcRn large subunit p51 antagonist |
| Penpulimab | Phase 3 | PDCD1 | Programmed cell death protein 1 inhibitor |
| Telisotuzumab vedotin | Phase 3 | Tubulin, MET | Tubulin inhibitor |
| Axatilimab | Phase 2 | CSF1R | Macrophage colony stimulating factor receptor inhibitor |
| Sibeprenlimab | Phase 2 | TNFSF13 | Tumor necrosis factor ligand superfamily member 13 inhibitor |
| Pivekimab sunirine | Phase 1 | IL3RA, DNA | Interleukin-3 receptor subunit alpha binding agent |
| Capromab pendetide | — | — | Diagnostic agent |
| Imciromab pentetate | — | — | Diagnostic (monoclonal antibody that is labelled with Indium (111In) for imaging) |
| Adalimumab | Approved | TNF | TNF-alpha inhibitor |
| Arcitumomab | Approved | CEACAM5 | Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent |
| Atoltivimab | Approved | GP | Envelope glycoprotein inhibitor |
| Besilesomab | Approved | — | Diagnostic agent |
| Bevacizumab | Approved | VEGFA | Vascular endothelial growth factor A inhibitor |
| Bevacizumab gamma | Approved | VEGFA | Vascular endothelial growth factor A binding agent |
| Catumaxomab | Approved | T cell surface glycoprotein CD3, EPCAM | T cell surface glycoprotein CD3 cross-linking agent |
| Concizumab | Approved | TFPI | Tissue factor pathway inhibitor inhibitor |
| Denosumab | Approved | TNFSF11 | Tumor necrosis factor ligand superfamily member 11 inhibitor |
| Dinutuximab beta | Approved | Disialoganglioside GD2 | Disialoganglioside GD2 inhibitor |
| Eculizumab | Approved | C5 | Complement C5 inhibitor |
| Efalizumab | Approved | ITGAL, ITGB2 | Integrin alpha-L/beta-2 (LFA-1) inhibitor |
| Golimumab | Approved | TNF | TNF-alpha inhibitor |
| Igovomab | Approved | MUC16 | Mucin-16 binding agent |
| Infliximab | Approved | TNF | TNF-alpha inhibitor |
| Maftivimab | Approved | GP | Envelope glycoprotein inhibitor |
| Natalizumab | Approved | ITGA4, ITGB7, ITGA4, ITGB1 | Integrin alpha-4/beta-7 inhibitor |
| Odesivimab | Approved | GP | Envelope glycoprotein inhibitor |
| Omalizumab | Approved | IGHE | Ig epsilon chain C region inhibitor |
| Pertuzumab | Approved | ERBB2 | Receptor protein-tyrosine kinase erbB-2 inhibitor |
| Ranibizumab | Approved | VEGFA | Vascular endothelial growth factor A inhibitor |
| Regdanvimab | Approved | S | Spike glycoprotein inhibitor |
| Rituximab | Approved | MS4A1 | B-lymphocyte antigen CD20 binding agent |
| Sotrovimab | Approved | S | Spike glycoprotein inhibitor |
| Sugemalimab | Approved | CD274 | Programmed cell death 1 ligand 1 binding agent |
| Sulesomab | Approved | — | Diagnostic agent |
| Tocilizumab | Approved | IL6R | Interleukin-6 receptor alpha subunit inhibitor |
| Trastuzumab | Approved | ERBB2 | Receptor protein-tyrosine kinase erbB-2 inhibitor |
| Trastuzumab deruxtecan | Approved | ERBB2, TOP1 | Receptor protein-tyrosine kinase erbB-2 binding agent |
| Trastuzumab emtansine | Approved | ERBB2, Tubulin | Receptor protein-tyrosine kinase erbB-2 binding agent |
| Ustekinumab | Approved | IL12A, IL12B, IL12B, IL23A | Interleukin-12 inhibitor |
| Votumumab | Approved | — | Diagnostic agent |
| Abelacimab | Phase 3 | F11 | Coagulation factor XI inhibitor |
| Adebrelimab | Phase 3 | CD274 | Programmed cell death 1 ligand 1 inhibitor |
| Alnuctamab | Phase 3 | — | — |
| Amlitelimab | Phase 3 | TNFSF4 | Tumor necrosis factor ligand superfamily member 4 inhibitor |
| Amubarvimab | Phase 3 | S | Spike glycoprotein inhibitor |
| Andecaliximab | Phase 3 | MMP9 | Matrix metalloproteinase 9 inhibitor |
| Anselamimab | Phase 3 | — | — |
| Astegolimab | Phase 3 | IL1RAP, IL1RL1 | IL-33 receptor (ST2) inhibitor |
| Balstilimab | Phase 3 | PDCD1 | Programmed cell death protein 1 antagonist |
| Bamlanivimab | Phase 3 | S | Spike glycoprotein inhibitor |
| Bapineuzumab | Phase 3 | APP | Amyloid-beta A4 protein binding agent |
| Barzolvolimab | Phase 3 | — | — |
| Batoclimab | Phase 3 | FCGRT | IgG receptor FcRn large subunit p51 inhibitor |
| Bavituximab | Phase 3 | Phosphatidylserine | Phosphatidylserine inhibitor |
| Begelomab | Phase 3 | DPP4 | Dipeptidyl peptidase IV inhibitor |
| Bentracimab | Phase 3 | Ticagrelor | Ticagrelor sequestering agent |
| Bermekimab | Phase 3 | IL1A | Interleukin-1 alpha inhibitor |
| Bimagrumab | Phase 3 | ACVR2B | Activin receptor type-2B antagonist |
| Birtamimab | Phase 3 | Light chain aggregates | Light chain aggregates inhibitor |
| Bococizumab | Phase 3 | PCSK9 | Subtilisin/kexin type 9 inhibitor |
| Brazikumab | Phase 3 | IL12B, IL23A | Interleukin-23 inhibitor |
| Briakinumab | Phase 3 | IL12B, IL23A, IL12A, IL12B | Interleukin-23 inhibitor |
| Cadonilimab | Phase 3 | PDCD1, CTLA4 | Programmed cell death protein 1 inhibitor |
| Camrelizumab | Phase 3 | PDCD1 | Programmed cell death protein 1 antagonist |
| Carotuximab | Phase 3 | ENG | Endoglin inhibitor |
| Casirivimab | Phase 3 | S | Spike glycoprotein inhibitor |
| Cendakimab | Phase 3 | IL13 | Interleukin-13 inhibitor |
| Certolizumab | Phase 3 | — | — |
| Cetrelimab | Phase 3 | PDCD1 | Programmed cell death protein 1 inhibitor |
| Cilgavimab | Phase 3 | S | Spike glycoprotein blocker |
| Crenezumab | Phase 3 | APP | Amyloid-beta A4 protein inhibitor |
| Dapirolizumab pegol | Phase 3 | CD40LG | CD40 ligand inhibitor |
| Depatuxizumab mafodotin | Phase 3 | EGFR, Tubulin | Epidermal growth factor receptor erbB1 binding agent |
| Disitamab vedotin | Phase 3 | ERBB2, Tubulin | Receptor tyrosine-protein kinase erbB-2 binding agent |
| Divozilimab | Phase 3 | — | — |
| Domvanalimab | Phase 3 | TIGIT | T-cell immunoreceptor with Ig and ITIM domains inhibitor |
| Ebdarokimab | Phase 3 | IL12A, IL12B, IL12B, IL23A | Interleukin-12 inhibitor |
| Edrecolomab | Phase 3 | EPCAM | Epithelial cell adhesion molecule cross-linking agent |
| Emactuzumab | Phase 3 | CSF1R | Macrophage colony stimulating factor receptor inhibitor |
| Envafolimab | Phase 3 | CD274 | Programmed cell death 1 ligand 1 binding agent |
| Epratuzumab | Phase 3 | CD22 | CD22 inhibitor |
| Erfonrilimab | Phase 3 | CTLA4, CD274 | Cytotoxic T-lymphocyte protein 4 inhibitor |
| Etesevimab | Phase 3 | S | Spike glycoprotein inhibitor |
| Etrolizumab | Phase 3 | ITGB7 | Integrin beta-7 antagonist |
| Farletuzumab | Phase 3 | FOLR1 | Folate receptor alpha inhibitor |
| Fasinumab | Phase 3 | NGF | Beta-nerve growth factor inhibitor |
| Favezelimab | Phase 3 | LAG3 | Lymphocyte activation gene 3 protein inhibitor |
| Felzartamab | Phase 3 | CD38 | Lymphocyte differentiation antigen CD38 inhibitor |
| Fianlimab | Phase 3 | LAG3 | Lymphocyte activation gene 3 protein inhibitor |
| Ficlatuzumab | Phase 3 | HGF | Hepatocyte growth factor inhibitor |
| Figitumumab | Phase 3 | IGF1R | Insulin-like growth factor I receptor antagonist |
| Finotonlimab | Phase 3 | PDCD1 | Programmed cell death protein 1 inhibitor |
| Frexalimab | Phase 3 | — | — |
| Fulranumab | Phase 3 | NGF | Beta-nerve growth factor inhibitor |
| Galiximab | Phase 3 | CD80 | T-lymphocyte activation antigen CD80 inhibitor |
| Gantenerumab | Phase 3 | APP | Amyloid-beta A4 protein binding agent |
| Gefurulimab | Phase 3 | — | — |
| Gemtuzumab | Phase 3 | CD33 | Myeloid cell surface antigen CD33 binding agent |
| Gevokizumab | Phase 3 | IL1B | Interleukin-1 beta negative allosteric modulator |
| Girentuximab | Phase 3 | CA9 | Carbonic anhydrase IX other |
| Gumokimab | Phase 3 | — | — |
| Ianalumab | Phase 3 | TNFRSF13C | Tumor necrosis factor receptor superfamily member 13C binding agent |
| Ifinatamab deruxtecan | Phase 3 | — | — |
| Imdevimab | Phase 3 | S | Spike glycoprotein inhibitor |
| Inolimomab | Phase 3 | IL2RA | Interleukin-2 receptor alpha chain antagonist |
| Inotuzumab | Phase 3 | CD22 | CD22 binding agent |
| Itepekimab | Phase 3 | IL33 | Interleukin-33 inhibitor |
| Itolizumab | Phase 3 | CD6 | T-cell differentiation antigen CD6 inhibitor |
| Ivonescimab | Phase 3 | — | — |
| Lampalizumab | Phase 3 | CFD | Complement factor D inhibitor |
| Latozinemab | Phase 3 | — | — |
| Lemzoparlimab | Phase 3 | — | — |
| Lenzilumab | Phase 3 | CSF2 | Granulocyte-macrophage colony-stimulating factor inhibitor |
| Leronlimab | Phase 3 | CCR5 | C-C chemokine receptor type 5 antagonist |
| Levilimab | Phase 3 | IL6R | Interleukin-6 receptor alpha subunit inhibitor |
| Ligelizumab | Phase 3 | IGHE | Ig epsilon chain C region inhibitor |
| Lintuzumab | Phase 3 | CD33 | Myeloid cell surface antigen CD33 other |
| Lirentelimab | Phase 3 | SIGLEC8 | Sialic acid-binding Ig-like lectin 8 inhibitor |
| Litifilimab | Phase 3 | CLEC4C | C-type lectin domain family 4 member C inhibitor |
| Lutikizumab | Phase 3 | IL1A, IL1B | Interleukin-1 alpha inhibitor |
| Magrolimab | Phase 3 | CD47 | Leukocyte surface antigen CD47 inhibitor |
| Mitumomab | Phase 3 | Ganglioside GD3 | Ganglioside GD3 other |
| Monalizumab | Phase 3 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein inhibitor |
| Motavizumab | Phase 3 | F | Fusion glycoprotein F0 inhibitor |
| Mupadolimab | Phase 3 | — | — |
| Nimotuzumab | Phase 3 | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Obexelimab | Phase 3 | CD19, FCGR2B | B-lymphocyte antigen CD19 inhibitor |
| Ociperlimab | Phase 3 | TIGIT | T-cell immunoreceptor with Ig and ITIM domains inhibitor |
| Odronextamab | Phase 3 | MS4A1, T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20 binding agent |
| Oleclumab | Phase 3 | NT5E | 5'-nucleotidase inhibitor |
| Olokizumab | Phase 3 | IL6 | Interleukin-6 inhibitor |
| Onartuzumab | Phase 3 | MET | Hepatocyte growth factor receptor antagonist |
| Ongericimab | Phase 3 | PCSK9 | Subtilisin/kexin type 9 inhibitor |
| Ontamalimab | Phase 3 | MADCAM1 | Mucosal addressin cell adhesion molecule-1 inhibitor |
| Oportuzumab monatox | Phase 3 | EPCAM, EEF2 | Epithelial cell adhesion molecule binding agent |
| Oregovomab | Phase 3 | MUC16 | Mucin-16 other |
| Otelixizumab | Phase 3 | CD3E | T-cell surface glycoprotein CD3 epsilon chain binding agent |
| Otilimab | Phase 3 | CSF2 | Granulocyte-macrophage colony-stimulating factor inhibitor |
| Pamrevlumab | Phase 3 | CCN2 | Connective tissue growth factor inhibitor |
| Patritumab | Phase 3 | ERBB3 | Receptor tyrosine-protein kinase erbB-3 inhibitor |
| Patritumab deruxtecan | Phase 3 | ERBB3, TOP1 | Receptor tyrosine-protein kinase erbB-3 binding agent |
| Pexelizumab | Phase 3 | C5 | Complement C5 inhibitor |
| Prolgolimab | Phase 3 | — | — |
| Pucotenlimab | Phase 3 | PDCD1 | Programmed cell death protein 1 inhibitor |
| Pulocimab | Phase 3 | — | — |
| Quavonlimab | Phase 3 | CTLA4 | Cytotoxic T-lymphocyte protein 4 inhibitor |
| Racotumomab | Phase 3 | Ganglioside GM3 (NeuGcGM3) | Ganglioside GM3 (NeuGcGM3) inhibitor |
| Recaticimab | Phase 3 | — | — |
| Relatlimab | Phase 3 | LAG3 | Lymphocyte activation gene 3 protein inhibitor |
| Rilotumumab | Phase 3 | HGF | Hepatocyte growth factor inhibitor |
| Ripertamab | Phase 3 | — | — |
| Rocatinlimab | Phase 3 | TNFRSF4 | Tumor necrosis factor receptor superfamily member 4 antagonist |
| Romlusevimab | Phase 3 | S | Spike glycoprotein inhibitor |
| Rovalpituzumab tesirine | Phase 3 | DLL3, DNA | Delta-like protein 3 binding agent |
| Sabatolimab | Phase 3 | HAVCR2 | Hepatitis A virus cellular receptor 2 inhibitor |
| Sacituzumab tirumotecan | Phase 3 | — | — |
| Sasanlimab | Phase 3 | PDCD1 | Programmed cell death protein 1 antagonist |
| Semzuvolimab | Phase 3 | CD4 | T-cell surface antigen CD4 inhibitor |
| Serplulimab | Phase 3 | PDCD1 | Programmed cell death protein 1 antagonist |
| Setrusumab | Phase 3 | SOST | Sclerostin inhibitor |
| Sintilimab | Phase 3 | PDCD1 | Programmed cell death protein 1 antagonist |
| Sirukumab | Phase 3 | IL6 | Interleukin-6 inhibitor |
| Socazolimab | Phase 3 | CD274 | Programmed cell death 1 ligand 1 inhibitor |
| Solanezumab | Phase 3 | APP | Amyloid-beta A4 protein binding agent |
| Spartalizumab | Phase 3 | PDCD1 | Programmed cell death protein 1 antagonist |
| Suptavumab | Phase 3 | F | Fusion glycoprotein F0 inhibitor |
| Surzebiclimab | Phase 3 | — | — |
| Tabalumab | Phase 3 | TNFSF13B | Tumor necrosis factor ligand superfamily member 13B inhibitor |
| Tafolecimab | Phase 3 | PCSK9 | Subtilisin/kexin type 9 inhibitor |
| Tanezumab | Phase 3 | NGF | Beta-nerve growth factor inhibitor |
| Tifcemalimab | Phase 3 | — | — |
| Tiragolumab | Phase 3 | TIGIT | T-cell immunoreceptor with Ig and ITIM domains inhibitor |
| Tixagevimab | Phase 3 | S | Spike glycoprotein blocker |
| Tositumomab | Phase 3 | MS4A1 | B-lymphocyte antigen CD20 binding agent |
| Tositumomab 131I | Phase 3 | MS4A1 | B-lymphocyte antigen CD20 binding agent |
| Tozorakimab | Phase 3 | — | — |
| Trastuzumab duocarmazine | Phase 3 | ERBB2, DNA | Receptor protein-tyrosine kinase erbB-2 binding agent |
| Trastuzumab envedotin | Phase 3 | — | — |
| Trastuzumab vedotin | Phase 3 | — | — |
| Tusamitamab ravtansine | Phase 3 | CEACAM5, Tubulin | Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent |
| Utomilumab | Phase 3 | TNFRSF9 | Tumor necrosis factor receptor superfamily member 9 agonist |
| Vibostolimab | Phase 3 | TIGIT | T-cell immunoreceptor with Ig and ITIM domains antagonist |
| Vilobelimab | Phase 3 | C5 | Complement C5 inhibitor |
| Visilizumab | Phase 3 | CD3E | T-cell surface glycoprotein CD3 epsilon chain inhibitor |
| Vunakizumab | Phase 3 | IL17A | Interleukin 17A inhibitor |
| Zalutumumab | Phase 3 | EGFR | Epidermal growth factor receptor erbB1 antagonist |
| Zanolimumab | Phase 3 | CD4 | T-cell surface antigen CD4 other |
| Zimberelimab | Phase 3 | PDCD1 | Programmed cell death protein 1 inhibitor |
| Abagovomab | Phase 2 | MUC16 | Mucin-16 other |
| Abituzumab | Phase 2 | ITGAV, ITGB1, ITGAV, ITGB3, ITGAV, ITGB5, ITGAV, ITGB6 and 1 more | Integrin alpha-V/beta-1 inhibitor |
| Abrilumab | Phase 2 | ITGA4, ITGB7 | Integrin alpha-4/beta-7 inhibitor |
| Acasunlimab | Phase 2 | — | — |
| Acrixolimab | Phase 2 | — | — |
| Adalimumab fosimdesonide | Phase 2 | — | — |
| Adecatumumab | Phase 2 | EPCAM | Epithelial cell adhesion molecule inhibitor |
| Adintrevimab | Phase 2 | S | Spike glycoprotein inhibitor |
| Afelimomab | Phase 2 | TNF | TNF-alpha inhibitor |
| Alemtuzumab beta | Phase 2 | CD52 | CAMPATH-1 antigen binding agent |
| Amatuximab | Phase 2 | MSLN | Mesothelin inhibitor |
| Anetumab ravtansine | Phase 2 | MSLN, Tubulin | Mesothelin binding agent |
| Anrukinzumab | Phase 2 | IL13 | Interleukin-13 inhibitor |
| Anumigilimab | Phase 2 | CSF3R | Granulocyte colony stimulating factor receptor antagonist |
| Apolizumab | Phase 2 | Human leukocyte antigen DR beta chain | Human leukocyte antigen DR beta chain inhibitor |
| Ascrinvacumab | Phase 2 | ACVRL1 | Serine/threonine-protein kinase receptor R3 inhibitor |
| Avdoralimab | Phase 2 | C5AR1 | C5a anaphylatoxin chemotactic receptor inhibitor |
| Basiliximab sarotalocan | Phase 2 | — | — |
| Bebtelovimab | Phase 2 | S | Spike glycoprotein inhibitor |
| Bemarituzumab | Phase 2 | FGFR2, FCGR3A | Fibroblast growth factor receptor 2 inhibitor |
| Bepranemab | Phase 2 | MAPT | Microtubule-associated protein tau inhibitor |
| Bertilimumab | Phase 2 | CCL11 | Eotaxin inhibitor |
| Betfisolimab | Phase 2 | — | — |
| Bleselumab | Phase 2 | CD40 | Tumor necrosis factor receptor superfamily member 5 inhibitor |
| Blosozumab | Phase 2 | SOST | Sclerostin inhibitor |
| Boserolimab | Phase 2 | — | — |
| Botensilimab | Phase 2 | — | — |
| Budigalimab | Phase 2 | PDCD1 | Programmed cell death protein 1 inhibitor |
| Burfiralimab | Phase 2 | — | — |
| Cabiralizumab | Phase 2 | CSF1R | Macrophage colony stimulating factor receptor antagonist |
| Camidanlumab tesirine | Phase 2 | IL2RA, DNA | Interleukin-2 receptor alpha chain binding agent |
| Camoteskimab | Phase 2 | IL18 | Interleukin-18 cross-linking agent |
| Cantuzumab ravtansine | Phase 2 | MUC1, Tubulin | Mucin-1 binding agent |
| Carlumab | Phase 2 | CCL2 | C-C motif chemokine 2 inhibitor |
| Cetuximab beta | Phase 2 | — | — |
| Cevostamab | Phase 2 | — | — |
| Cifurtilimab | Phase 2 | — | — |
| Cinpanemab | Phase 2 | SNCA | Alpha-synuclein inhibitor |
| Cirmtuzumab | Phase 2 | ROR1 | Inactive tyrosine-protein kinase transmembrane receptor ROR1 inhibitor |
| Cixutumumab | Phase 2 | IGF1R | Insulin-like growth factor I receptor antagonist |
| Clazakizumab | Phase 2 | IL6 | Interleukin-6 inhibitor |
| Cobolimab | Phase 2 | HAVCR2 | Hepatitis A virus cellular receptor 2 inhibitor |
| Codrituzumab | Phase 2 | Ganglioside GD3, GPC3 | Ganglioside GD3 other |
| Coltuximab ravtansine | Phase 2 | CD19, Tubulin | B-lymphocyte antigen CD19 binding agent |
| Cosfroviximab | Phase 2 | GP | Envelope glycoprotein inhibitor |
| Cusatuzumab | Phase 2 | CD70 | CD70 antigen inhibitor |
| Dacetuzumab | Phase 2 | CD40 | Tumor necrosis factor receptor superfamily member 5 inhibitor |
| Dalotuzumab | Phase 2 | IGF1R | Insulin-like growth factor I receptor antagonist |
| Daxdilimab | Phase 2 | LILRA4 | Leukocyte immunoglobulin-like receptor subfamily A member 4 inhibitor |
| Demcizumab | Phase 2 | DLL4 | Delta-like protein 4 inhibitor |
| Denintuzumab mafodotin | Phase 2 | CD19, Tubulin | B-lymphocyte antigen CD19 binding agent |
| Depatuxizumab | Phase 2 | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Detumomab | Phase 2 | — | Unknown |
| Dezamizumab | Phase 2 | APCS | Serum amyloid P-component inhibitor |
| Dilpacimab | Phase 2 | — | — |
| Diridavumab | Phase 2 | HA | Hemagglutinin inhibitor |
| Domagrozumab | Phase 2 | MSTN | Growth/differentiation factor 8 inhibitor |
| Drozitumab | Phase 2 | TNFRSF10B | Tumor necrosis factor receptor superfamily member 10B agonist |
| Duligotuzumab | Phase 2 | EGFR, ERBB3 | Epidermal growth factor receptor erbB1 inhibitor |
| Dusigitumab | Phase 2 | IGF1, IGF2 | Insulin-like growth factor I inhibitor |
| Ecromeximab | Phase 2 | Ganglioside GD3 | Ganglioside GD3 other |
| Efungumab | Phase 2 | HSP90 | Heat shock protein 90 homolog inhibitor |
| Eldelumab | Phase 2 | CXCL10 | C-X-C motif chemokine 10 inhibitor |
| Elezanumab | Phase 2 | RGMA | Repulsive guidance molecule A inhibitor |
| Emibetuzumab | Phase 2 | MET | Hepatocyte growth factor receptor inhibitor |
| Enibarcimab | Phase 2 | ADM | ADM stabiliser |
| Enoblituzumab | Phase 2 | CD276 | CD276 antigen cross-linking agent |
| Enokizumab | Phase 2 | IL9 | Interleukin-9 inhibitor |
| Ertumaxomab | Phase 2 | ERBB2, CD3E | Receptor protein-tyrosine kinase erbB-2 cross-linking agent |
| Etaracizumab | Phase 2 | ITGAV, ITGB3 | Integrin alpha-V/beta-3 antagonist |
| Etigilimab | Phase 2 | TIGIT | T-cell immunoreceptor with Ig and ITIM domains inhibitor |
| Etokimab | Phase 2 | IL33 | Interleukin-33 binding agent |
| Exbivirumab | Phase 2 | S | Major surface antigen binding agent |
| Ezabenlimab | Phase 2 | — | — |
| Farletuzumab ecteribulin | Phase 2 | — | — |
| Fazpilodemab | Phase 2 | FGF1, KLB | FGF1/KLB agonist |
| Feladilimab | Phase 2 | ICOS | Inducible T-cell costimulator agonist |
| Fezakinumab | Phase 2 | IL22 | Interleukin-22 inhibitor |
| Fiztasovimab | Phase 2 | — | — |
| Fletikumab | Phase 2 | IL20 | Interleukin-20 inhibitor |
| Flotetuzumab | Phase 2 | IL3RA, T cell surface glycoprotein CD3 | Interleukin-3 receptor subunit alpha binding agent |
| Fontolizumab | Phase 2 | IFNG | Interferon gamma inhibitor |
| Foralumab | Phase 2 | T cell surface glycoprotein CD3 | T cell surface glycoprotein CD3 inhibitor |
| Fresolimumab | Phase 2 | TGFB1, TGFB2, TGFB3 | Transforming growth factor beta-1 inhibitor |
| Frovocimab | Phase 2 | PCSK9 | Subtilisin/kexin type 9 inhibitor |
| Futuximab | Phase 2 | EGFR | Epidermal growth factor receptor erbB1 antagonist |
| Galegenimab | Phase 2 | — | — |
| Gancotamab | Phase 2 | ERBB2, DNA, TOP2A | Receptor protein-tyrosine kinase erbB-2 binding agent |
| Ganitumab | Phase 2 | IGF1R | Insulin-like growth factor I receptor antagonist |
| Gavilimomab | Phase 2 | BSG | Basigin other |
| Gedivumab | Phase 2 | HA | Hemagglutinin inhibitor |
| Gimsilumab | Phase 2 | CSF2 | Granulocyte-macrophage colony-stimulating factor inhibitor |
| Glembatumumab vedotin | Phase 2 | GPNMB, Tubulin | Transmembrane glycoprotein NMB binding agent |
| Glenzocimab | Phase 2 | GP6 | Platelet glycoprotein VI (GPVI) inhibitor |
| Golocdacimab | Phase 2 | — | — |
| Gosuranemab | Phase 2 | MAPT | Microtubule-associated protein tau inhibitor |
| Icrucumab | Phase 2 | FLT1 | Vascular endothelial growth factor receptor 1 antagonist |
| Ieramilimab | Phase 2 | LAG3 | Lymphocyte activation gene 3 protein inhibitor |
| Ifinatamab | Phase 2 | — | — |
| Imgatuzumab | Phase 2 | EGFR, FCGR3A | Epidermal growth factor receptor erbB1 antagonist |
| Imsidolimab | Phase 2 | IL1RAP, IL1RL2 | IL36 receptor antagonist |
| Inclacumab | Phase 2 | SELP | P-selectin antagonist |
| Indusatumab vedotin | Phase 2 | Tubulin, GUCY2C | Tubulin inhibitor |
| Inezetamab | Phase 2 | — | — |
| Intetumumab | Phase 2 | ITGAV, ITGB3, ITGAV, ITGB5 | Integrin alpha-V/beta-3 antagonist |
| Iratumumab | Phase 2 | TNFRSF8 | Tumor necrosis factor receptor superfamily member 8 other |
| Iscalimab | Phase 2 | CD40 | Tumor necrosis factor receptor superfamily member 5 inhibitor |
| Ispectamab debotansine | Phase 2 | — | — |
| Ispectamab tazide | Phase 2 | — | — |
| Istiratumab | Phase 2 | ERBB3, IGF1R | Receptor tyrosine-protein kinase erbB-3 inhibitor |
| Ivuxolimab | Phase 2 | TNFRSF4 | Tumor necrosis factor receptor superfamily member 4 agonist |
| Izalontamab | Phase 2 | — | — |
| Izalontamab brengitecan | Phase 2 | — | — |
| Izuralimab | Phase 2 | — | — |
| Lacutamab | Phase 2 | KIR3DL2 | Killer cell immunoglobulin-like receptor 3DL2 antagonist |
| Ladiratuzumab vedotin | Phase 2 | Tubulin, SLC39A6 | Tubulin inhibitor |
| Landogrozumab | Phase 2 | MSTN | Growth/differentiation factor 8 inhibitor |
| Larcaviximab | Phase 2 | GP | Envelope glycoprotein inhibitor |
| Lenvervimab | Phase 2 | — | — |
| Lesabelimab | Phase 2 | — | — |
| Libivirumab | Phase 2 | S | Major surface antigen binding agent |
| Licaminlimab | Phase 2 | — | — |
| Lifastuzumab vedotin | Phase 2 | Tubulin, SLC34A2 | Tubulin inhibitor |
| Lirilumab | Phase 2 | KIR2DL1, KIR2DL2, KIR2DL3 | Killer cell immunoglobulin-like receptor 2DL1 inhibitor |
| Livmoniplimab | Phase 2 | — | — |
| Lorvotuzumab mertansine | Phase 2 | NCAM1, Tubulin | Neural cell adhesion molecule 1 binding agent |
| Lulizumab pegol | Phase 2 | CD28 | T-cell-specific surface glycoprotein CD28 antagonist |
| Lumiliximab | Phase 2 | FCER2 | Immunoglobulin epsilon Fc receptor antagonist |
| Lusvertikimab | Phase 2 | — | — |
| Mapatumumab | Phase 2 | TNFRSF10A | TRAIL receptor-1 agonist |
| Matuzumab | Phase 2 | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Mavrilimumab | Phase 2 | CSF2RA, CSF2RB | Granulocyte-macrophage colony-stimulating factor receptor antagonist |
| Mecbotamab | Phase 2 | — | — |
| Mecbotamab vedotin | Phase 2 | AXL, Tubulin | Tyrosine-protein kinase receptor UFO binding agent |
| Melrilimab | Phase 2 | — | — |
| Mezagitamab | Phase 2 | CD38 | Lymphocyte differentiation antigen CD38 binding agent |
| Mibavademab | Phase 2 | LEPR | Leptin receptor agonist |
| Murlentamab | Phase 2 | — | — |
| Namilumab | Phase 2 | CSF2 | Granulocyte-macrophage colony-stimulating factor inhibitor |
| Naptumomab estafenatox | Phase 2 | TPBG | Trophoblast glycoprotein other |
| Neihulizumab | Phase 2 | SELPLG | P-selectin glycoprotein ligand 1 inhibitor |
| Nesvacumab | Phase 2 | ANGPT2 | Angiopoietin-2 inhibitor |
| Nimacimab | Phase 2 | CNR1 | Cannabinoid CB1 receptor negative allosteric modulator |
| Olendalizumab | Phase 2 | C5 | Complement C5 inhibitor |
| Olinvacimab | Phase 2 | KDR | Vascular endothelial growth factor receptor 2 inhibitor |
| Ontuxizumab | Phase 2 | CD248 | Endosialin inhibitor |
| Opicinumab | Phase 2 | LINGO1 | Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 inhibitor |
| Ordesekimab | Phase 2 | IL15 | Interleukin-15 inhibitor |
| Orilanolimab | Phase 2 | FCGRT | IgG receptor FcRn large subunit p51 antagonist |
| Osemitamab | Phase 2 | — | — |
| Oxelumab | Phase 2 | TNFSF4 | Tumor necrosis factor ligand superfamily member 4 inhibitor |
| Ozanezumab | Phase 2 | RTN4 | Reticulon-4 inhibitor |
| Ozoralizumab | Phase 2 | TNF | TNF-alpha inhibitor |
| Ozuriftamab | Phase 2 | — | — |
| Ozuriftamab vedotin | Phase 2 | — | — |
| Pacmilimab | Phase 2 | CD274 | Programmed cell death 1 ligand 1 binding agent |
| Pagibaximab | Phase 2 | Lipoteichoic acid | Lipoteichoic acid inhibitor |
| Parsatuzumab | Phase 2 | EGFL7 | Epidermal growth factor-like protein 7 inhibitor |
| Pascolizumab | Phase 2 | IL4 | Interleukin-4 inhibitor |
| Pateclizumab | Phase 2 | LTA | TNF-beta inhibitor |
| Pelgifatamab | Phase 2 | — | — |
| Pepinemab | Phase 2 | SEMA4D | Semaphorin-4D inhibitor |
| Peresolimab | Phase 2 | — | — |
| Pertuzumab zuvotolimod | Phase 2 | — | — |
| Pidilizumab | Phase 2 | PDCD1 | Programmed cell death protein 1 inhibitor |
| Pimivalimab | Phase 2 | PDCD1 | Programmed cell death protein 1 inhibitor |
| Pimurutamab | Phase 2 | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Placulumab | Phase 2 | TNF | TNF-alpha inhibitor |
| Plamotamab | Phase 2 | — | — |
| Plonmarlimab | Phase 2 | CSF2 | Granulocyte-macrophage colony-stimulating factor antagonist |
| Plozalizumab | Phase 2 | CCR2 | C-C chemokine receptor type 2 inhibitor |
| Plutavimab | Phase 2 | — | — |
| Ponezumab | Phase 2 | APP | Amyloid-beta A4 protein binding agent |
| Porgaviximab | Phase 2 | GP | Envelope glycoprotein inhibitor |
| Praluzatamab ravtansine | Phase 2 | ALCAM, Tubulin | CD166 antigen binding agent |
| Prasinezumab | Phase 2 | SNCA | Alpha-synuclein binding agent |
| Quetmolimab | Phase 2 | CX3CL1 | Fractalkine inhibitor |
| Quilizumab | Phase 2 | IGHE | Ig epsilon chain C region inhibitor |
| Quisovalimab | Phase 2 | TNFSF14 | Tumor necrosis factor ligand superfamily member 14 inhibitor |
| Ragifilimab | Phase 2 | TNFRSF18 | Tumor necrosis factor receptor superfamily member 18 agonist |
| Ravagalimab | Phase 2 | CD40LG | CD40 ligand antagonist |
| Refanezumab | Phase 2 | MAG | Myelin-associated glycoprotein inhibitor |
| Remtolumab | Phase 2 | TNF, IL17A | TNF-alpha inhibitor |
| Reozalimab | Phase 2 | — | — |
| Rinucumab | Phase 2 | PDGFRB | Platelet-derived growth factor receptor beta inhibitor |
| Robatumumab | Phase 2 | IGF1R | Insulin-like growth factor I receptor antagonist |
| Romilkimab | Phase 2 | IL4, IL13 | Interleukin-4 inhibitor |
| Rontalizumab | Phase 2 | Interferon alpha | Interferon alpha inhibitor |
| Rosnilimab | Phase 2 | — | — |
| Ruplizumab | Phase 2 | CD40LG | CD40 ligand inhibitor |
| Semorinemab | Phase 2 | MAPT | Microtubule-associated protein tau inhibitor |
| Seribantumab | Phase 2 | ERBB3 | Receptor tyrosine-protein kinase erbB-3 antagonist |
| Sevirumab | Phase 2 | GH | Envelope glycoprotein H inhibitor |
| Sifalimumab | Phase 2 | Interferon alpha | Interferon alpha inhibitor |
| Simtuzumab | Phase 2 | LOXL2 | Lysyl oxidase homolog 2 inhibitor |
| Siplizumab | Phase 2 | CD2 | T-cell surface antigen CD2 inhibitor |
| Sonepcizumab | Phase 2 | Sphingosine 1-phosphate | Sphingosine 1-phosphate inhibitor |
| Sotigalimab | Phase 2 | CD40 | Tumor necrosis factor receptor superfamily member 5 agonist |
| Suvratoxumab | Phase 2 | HLY | Alpha-hemolysin inhibitor |
| Talacotuzumab | Phase 2 | IL3RA | Interleukin-3 receptor subunit alpha binding agent |
| Tarcocimab tedromer | Phase 2 | — | — |
| Tebotelimab | Phase 2 | LAG3, PDCD1 | Lymphocyte activation gene 3 protein inhibitor |
| Telazorlimab | Phase 2 | TNFRSF4 | Tumor necrosis factor receptor superfamily member 4 antagonist |
| Telimomab aritox | Phase 2 | CD5, 80S Ribosome | T-cell surface glycoprotein CD5 binding agent |
| Telisotuzumab adizutecan | Phase 2 | — | — |
| Temelimab | Phase 2 | ERVW-1 | Syncytin-1 inhibitor |
| Teropavimab | Phase 2 | — | — |
| Tesidolumab | Phase 2 | C5 | Complement C5 binding agent |
| Tesnatilimab | Phase 2 | — | — |
| Tibulizumab | Phase 2 | TNFSF13B, IL17A | Tumor necrosis factor ligand superfamily member 13B inhibitor |
| Tigatuzumab | Phase 2 | TNFRSF10B | Tumor necrosis factor receptor superfamily member 10B agonist |
| Tilavonemab | Phase 2 | MAPT | Microtubule-associated protein tau inhibitor |
| Torudokimab | Phase 2 | IL33 | Interleukin-33 inhibitor |
| Tovetumab | Phase 2 | PDGFRA | Platelet-derived growth factor receptor alpha inhibitor |
| Trastuzumab botidotin | Phase 2 | ERBB2, Tubulin | Receptor tyrosine-protein kinase erbB-2 binding agent |
| Trastuzumab brengitecan | Phase 2 | — | — |
| Trastuzumab corixetan | Phase 2 | — | — |
| Trastuzumab imbotolimod | Phase 2 | — | — |
| Trastuzumab pamirtecan | Phase 2 | — | — |
| Trastuzumab rezetecan | Phase 2 | — | — |
| Tregalizumab | Phase 2 | CD4 | T-cell surface antigen CD4 agonist |
| Trevogrumab | Phase 2 | MSTN | Growth/differentiation factor 8 inhibitor |
| Tucotuzumab celmoleukin | Phase 2 | EPCAM | Epithelial cell adhesion molecule other |
| Unasnemab | Phase 2 | RGMA | Repulsive guidance molecule A inhibitor |
| Upanovimab | Phase 2 | — | — |
| Urelumab | Phase 2 | TNFRSF9 | Tumor necrosis factor receptor superfamily member 9 agonist |
| Vanucizumab | Phase 2 | VEGFA, ANGPT2 | Vascular endothelial growth factor A inhibitor |
| Varlilumab | Phase 2 | CD27 | CD27 antigen agonist |
| Vatelizumab | Phase 2 | ITGA2 | Integrin alpha-2 antagonist |
| Veltuzumab | Phase 2 | MS4A1 | B-lymphocyte antigen CD20 binding agent |
| Vibecotamab | Phase 2 | — | — |
| Visugromab | Phase 2 | — | — |
| Vixarelimab | Phase 2 | OSMR | Oncostatin-M-specific receptor subunit beta inhibitor |
| Vobarilizumab | Phase 2 | IL6R | Interleukin-6 receptor alpha subunit inhibitor |
| Vobramitamab | Phase 2 | — | — |
| Vobramitamab duocarmazine | Phase 2 | — | — |
| Volagidemab | Phase 2 | GCGR | Glucagon receptor inhibitor |
| Volociximab | Phase 2 | ITGA5, ITGB1 | Integrin alpha-5/beta-1 antagonist |
| Vonlerolizumab | Phase 2 | — | — |
| Vopratelimab | Phase 2 | ICOS | Inducible T-cell costimulator agonist |
| Vudalimab | Phase 2 | — | — |
| Xentuzumab | Phase 2 | IGF1, IGF2 | Insulin-like growth factor I inhibitor |
| Zagotenemab | Phase 2 | MAPT | Microtubule-associated protein tau inhibitor |
| Zalifrelimab | Phase 2 | CTLA4 | Cytotoxic T-lymphocyte protein 4 inhibitor |
| Zansecimab | Phase 2 | ANGPT2 | Angiopoietin-2 inhibitor |
| Zinlirvimab | Phase 2 | ENV | Envelope protein inhibitor |
| Acapatamab | Phase 1 | — | — |
| Aprutumab ixadotin | Phase 1 | FGFR2, Tubulin | Fibroblast growth factor receptor 2 binding agent |
| Atinumab | Phase 1 | RTN4 | Reticulon-4 inhibitor |
| Avizakimab | Phase 1 | — | — |
| Azintuxizumab vedotin | Phase 1 | Tubulin, SLAMF7 | Tubulin inhibitor |
| Bafisontamab | Phase 1 | MET, EGFR | Hepatocyte growth factor receptor inhibitor |
| Barecetamab | Phase 1 | — | — |
| Bavunalimab | Phase 1 | — | — |
| Belantamab | Phase 1 | — | — |
| Beludavimab | Phase 1 | — | — |
| Bexmarilimab | Phase 1 | — | — |
| Bivatuzumab | Phase 1 | CD44 | CD44 antigen binding agent |
| Briquilimab | Phase 1 | KIT | Stem cell growth factor receptor inhibitor |
| Brontictuzumab | Phase 1 | NOTCH1 | Neurogenic locus notch homolog protein 1 inhibitor |
| Cergutuzumab amunaleukin | Phase 1 | — | — |
| Cetuximab sarotalocan | Phase 1 | EGFR, Cell membrane | Epidermal growth factor receptor erbB1 binding agent |
| Cibisatamab | Phase 1 | — | — |
| Citatuzumab bogatox | Phase 1 | EPCAM, 80S Ribosome | Epithelial cell adhesion molecule binding agent |
| Clivatuzumab tetraxetan | Phase 1 | MUC5AC | Mucin-5AC binding agent |
| Cofetuzumab pelidotin | Phase 1 | — | — |
| Conatumumab | Phase 1 | TNFRSF10B | Tumor necrosis factor receptor superfamily member 10B agonist |
| Crefmirlimab | Phase 1 | — | — |
| Crotedumab | Phase 1 | GCGR | Glucagon receptor inhibitor |
| Cudarolimab | Phase 1 | — | — |
| Datopotamab | Phase 1 | — | — |
| Disitamab | Phase 1 | — | — |
| Elgemtumab | Phase 1 | ERBB3 | Receptor tyrosine-protein kinase erbB-3 inhibitor |
| Eluvixtamab | Phase 1 | — | — |
| Emerfetamab | Phase 1 | — | — |
| Emirodatamab | Phase 1 | — | — |
| Enoticumab | Phase 1 | DLL4 | Delta-like protein 4 inhibitor |
| Ensituximab | Phase 1 | MUC5AC | Mucin-5AC other |
| Epratuzumab 90Y | Phase 1 | CD22 | CD22 binding agent |
| Fianlimab dfo ZR-89 | Phase 1 | — | — |
| Flanvotumab | Phase 1 | TYRP1 | 5,6-dihydroxyindole-2-carboxylic acid oxidase other |
| Garivulimab | Phase 1 | — | — |
| Gatipotuzumab | Phase 1 | MUC1 | Mucin-1 inhibitor |
| Gatralimab | Phase 1 | — | — |
| Gentulizumab | Phase 1 | — | — |
| Giloralimab | Phase 1 | CD40 | Tumor necrosis factor receptor superfamily member 5 agonist |
| Glembatumumab | Phase 1 | GPNMB | Transmembrane glycoprotein NMB binding agent |
| Gremubamab | Phase 1 | PCRV, Psl | Low calcium response locus protein V inhibitor |
| Imaprelimab | Phase 1 | — | — |
| Imvotamab | Phase 1 | — | — |
| Indatuximab ravtansine | Phase 1 | SDC1, Tubulin | Syndecan-1 binding agent |
| Labetuzumab | Phase 1 | CEACAM5 | Carcinoembryonic antigen-related cell adhesion molecule 5 other |
| Letolizumab | Phase 1 | — | — |
| Lexatumumab | Phase 1 | TNFRSF10B | Tumor necrosis factor receptor superfamily member 10B agonist |
| Lilotomab | Phase 1 | — | — |
| Lodapolimab | Phase 1 | — | — |
| Lonigutamab | Phase 1 | — | — |
| Lorigerlimab | Phase 1 | — | — |
| Lucatumumab | Phase 1 | CD40 | Tumor necrosis factor receptor superfamily member 5 antagonist |
| Lumretuzumab | Phase 1 | ERBB3 | Receptor tyrosine-protein kinase erbB-3 inhibitor |
| Luveltamab tazevibulin | Phase 1 | — | — |
| Luveltamab tazide | Phase 1 | — | — |
| Milatuzumab | Phase 1 | CD74 | HLA-DR antigens-associated invariant chain antagonist |
| Minretumomab | Phase 1 | Tumor-associated antigen 72 | Tumor-associated antigen 72 binding agent |
| Mipasetamab | Phase 1 | — | — |
| Mipasetamab uzoptirine | Phase 1 | — | — |
| Mirzotamab | Phase 1 | — | — |
| Mirzotamab clezutoclax | Phase 1 | — | — |
| Mitazalimab | Phase 1 | — | — |
| Modotuximab | Phase 1 | EGFR | Epidermal growth factor receptor erbB1 antagonist |
| Naratuximab emtansine | Phase 1 | CD37 | Leukocyte antigen CD37 binding agent |
| Narnatumab | Phase 1 | MST1R | Macrophage-stimulating protein receptor inhibitor |
| Navicixizumab | Phase 1 | — | — |
| Nidanilimab | Phase 1 | — | — |
| Nivatrotamab | Phase 1 | — | — |
| Nurulimab | Phase 1 | — | — |
| Ocaratuzumab | Phase 1 | MS4A1 | B-lymphocyte antigen CD20 binding agent |
| Omburtamab | Phase 1 | — | — |
| Omodenbamab | Phase 1 | — | — |
| Onvatilimab | Phase 1 | — | — |
| Otlertuzumab | Phase 1 | CD37 | Leukocyte antigen CD37 binding agent |
| Pacanalotamab | Phase 1 | — | — |
| Pavurutamab | Phase 1 | — | — |
| Perakizumab | Phase 1 | IL17A | Interleukin 17A inhibitor |
| Petosemtamab | Phase 1 | — | — |
| Pinatuzumab vedotin | Phase 1 | CD22, Tubulin | CD22 binding agent |
| Pivekimab | Phase 1 | — | — |
| Ponsegromab | Phase 1 | — | — |
| Posdinemab | Phase 1 | MAPT | Microtubule-associated protein tau inhibitor |
| Praluzatamab | Phase 1 | — | — |
| Ralpancizumab | Phase 1 | PCSK9 | Subtilisin/kexin type 9 inhibitor |
| Revdofilimab | Phase 1 | — | — |
| Rosmantuzumab | Phase 1 | LGR4, RSPO3 | RSPO3-LGR4 inhibitor |
| Runimotamab | Phase 1 | — | — |
| Samalizumab | Phase 1 | CD200 | OX-2 membrane glycoprotein inhibitor |
| Samrotamab vedotin | Phase 1 | — | — |
| Selicrelumab | Phase 1 | CD40 | Tumor necrosis factor receptor superfamily member 5 agonist |
| Serclutamab | Phase 1 | — | — |
| Serclutamab talirine | Phase 1 | — | — |
| Sibrotuzumab | Phase 1 | FAP | Fibroblast activation protein alpha binding agent |
| Sofituzumab vedotin | Phase 1 | MUC16, Tubulin | Mucin-16 binding agent |
| Stamulumab | Phase 1 | MSTN | Growth/differentiation factor 8 inhibitor |
| Tarcocimab | Phase 1 | — | — |
| Tarextumab | Phase 1 | NOTCH3, NOTCH2 | Neurogenic locus notch homolog protein 3 inhibitor |
| Tavolimab | Phase 1 | — | — |
| Telisotuzumab | Phase 1 | MET | Hepatocyte growth factor receptor inhibitor |
| Tetulomab tetraxetan LU-177 | Phase 1 | — | — |
| Tidutamab | Phase 1 | — | — |
| Tilvestamab | Phase 1 | — | — |
| Timolumab | Phase 1 | — | — |
| Tisotumab | Phase 1 | — | — |
| Tomaralimab | Phase 1 | TLR2 | Toll-like receptor 2 antagonist |
| Tomuzotuximab | Phase 1 | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Tosatoxumab | Phase 1 | HLY | Alpha-hemolysin inhibitor |
| Trontinemab | Phase 1 | — | — |
| Tusamitamab | Phase 1 | — | — |
| Ubamatamab | Phase 1 | — | — |
| Uliledlimab | Phase 1 | — | — |
| Ulocuplumab | Phase 1 | CXCR4 | C-X-C chemokine receptor type 4 inhibitor |
| Urabrelimab | Phase 1 | — | — |
| Vadastuximab talirine | Phase 1 | — | — |
| Vandortuzumab vedotin | Phase 1 | STEAP1, Tubulin | Metalloreductase STEAP1 binding agent |
| Vantictumab | Phase 1 | FZD1, FZD2, FZD5, FZD7 and 1 more | Frizzled-1 antagonist |
| Vesencumab | Phase 1 | NRP1 | Neuropilin-1 inhibitor |
| Vofatamab | Phase 1 | FGFR3 | Fibroblast growth factor receptor 3 inhibitor |
| Vorsetuzumab mafodotin | Phase 1 | CD70, Tubulin | CD70 antigen binding agent |
| Vulinacimab | Phase 1 | — | — |
| Ziltivekimab | Phase 1 | IL6 | Interleukin-6 inhibitor |
| Alsevalimab | Early phase 1 | — | — |
| Actoxumab | — | TCDA | Toxin A inhibitor |
| Afasevikumab | — | IL17A | Interleukin 17A inhibitor |
| Alacizumab pegol | — | KDR | Vascular endothelial growth factor receptor 2 antagonist |
| Anatumomab mafenatox | — | TPBG | Trophoblast glycoprotein other |
| Apomab | — | TNFRSF10B | Tumor necrosis factor receptor superfamily member 10B agonist |
| Aselizumab | — | SELL | Leukocyte adhesion molecule-1 inhibitor |
| Atorolimumab | — | RHD | Blood group Rh(D) polypeptide other |
| Bectumomab | — | CD22 | CD22 other |
| Bevacizumab 111IN | — | VEGFA | Vascular endothelial growth factor A binding agent |
| Biciromab brallobarbital | — | FGB | Fibrinogen beta chain binding agent |
| Bivatuzumab mertansine | — | CD44, Tubulin | CD44 antigen binding agent |
| Cantuzumab mertansine | — | MUC1, Tubulin | Mucin-1 binding agent |
| Capromab | — | KLK3 | Prostate specific antigen binding agent |
| Cedelizumab | — | CD4 | T-cell surface antigen CD4 inhibitor |
| Clenoliximab | — | CD4 | T-cell surface antigen CD4 inhibitor |
| Denintuzumab | — | CD19 | B-lymphocyte antigen CD19 binding agent |
| Dorlimomab aritox | — | 80S Ribosome | 80S Ribosome inhibitor |
| Edobacomab | — | Lipopolysaccharide (LPS) | Lipopolysaccharide (LPS) other |
| Elsilimomab | — | IL6 | Interleukin-6 inhibitor |
| Enapotamab vedotin | — | Tubulin, AXL | Tubulin inhibitor |
| Enavatuzumab | — | TNFRSF12A | Tumor necrosis factor receptor superfamily member 12A agonist |
| Enlimomab | — | ICAM1 | Intercellular adhesion molecule-1 inhibitor |
| Enlimomab pegol | — | ICAM1 | Intercellular adhesion molecule-1 antagonist |
| Epitumomab | — | MUC1 | Mucin-1 binding agent |
| Epitumomab cituxetan | — | MUC1 | Mucin-1 binding agent |
| Erlizumab | — | ITGB2 | Integrin beta-2 negative modulator |
| Faralimomab | — | IFNA1, IFNA13 | Interferon alpha-1/13 binding agent |
| Felvizumab | — | F | Fusion glycoprotein F0 inhibitor |
| Foravirumab | — | G | Glycoprotein inhibitor |
| Ichorcumab | — | F2 | Thrombin inhibitor |
| Imalumab | — | MIF | Macrophage migration inhibitory factor inhibitor |
| Keliximab | — | CD4 | T-cell surface antigen CD4 negative modulator |
| Labetuzumab govitecan | — | CEACAM5, TOP1 | Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent |
| Lerdelimumab | — | TGFB2 | Transforming growth factor beta-2 inhibitor |
| Losatuxizumab vedotin | — | Tubulin, EGFR | Tubulin inhibitor |
| Maslimomab | — | T-cell receptor | T-cell receptor inhibitor |
| Metelimumab | — | TGFB1 | Transforming growth factor beta-1 inhibitor |
| Mirvetuximab | — | FOLR1 | Folate receptor alpha binding agent |
| Morolimumab | — | RHD | Blood group Rh(D) polypeptide inhibitor |
| Nacolomab tafenatox | — | MUC1 | Immunostimulant |
| Nebacumab | — | Lipopolysaccharide (LPS) | Lipopolysaccharide (LPS) inhibitor |
| Nerelimomab | — | TNF | TNF-alpha inhibitor |
| Netakimab | — | — | — |
| Odulimomab | — | ITGAL | Leukocyte adhesion glycoprotein LFA-1 alpha inhibitor |
| Orticumab | — | Oxidized LDL | Oxidized LDL inhibitor |
| Osocimab | — | F11 | Coagulation factor XI negative allosteric modulator |
| Panobacumab | — | Lipopolysaccharide (LPS) | Lipopolysaccharide (LPS) inhibitor |
| Pemtumomab | — | MUC1 | Mucin-1 binding agent |
| Priliximab | — | CD4 | T-cell surface antigen CD4 negative modulator |
| Pritumumab | — | VIM | Vimentin other |
| Radretumab | — | FN1 | Fibronectin binding agent |
| Rafivirumab | — | G | Glycoprotein inhibitor |
| Regavirumab | — | GB | Envelope glycoprotein B inhibitor |
| Roledumab | — | RHD | Blood group Rh(D) polypeptide inhibitor |
| Rovelizumab | — | ITGAM, ITGB2, ITGAL, ITGB2 | Integrin alpha-M/beta-2 antagonist |
| Solitomab | — | T cell surface glycoprotein CD3, EPCAM | T cell surface glycoprotein CD3 cross-linking agent |
| Sontuzumab | — | MUC1 | Mucin-1 other |
| Tadocizumab | — | ITGA2B, ITGB3 | Integrin alpha-IIb/beta-3 antagonist |
| Talizumab | — | IGHE | Ig epsilon chain C region inhibitor |
| Taplitumomab paptox | — | CD19, 80S Ribosome | B-lymphocyte antigen CD19 binding agent |
| Tefibazumab | — | CLFA | Clumping factor A inhibitor |
| Tenatumomab | — | TNC | Tenascin other |
| Teneliximab | — | CD40 | Tumor necrosis factor receptor superfamily member 5 partial agonist |
| Toralizumab | — | CD40LG | CD40 ligand inhibitor |
| Tuvirumab | — | S | Major surface antigen inhibitor |
| Urtoxazumab | — | STXB | Shiga toxin subunit B inhibitor |
| Vepalimomab | — | AOC3 | Amine oxidase, copper containing inhibitor |
| Vorsetuzumab | — | CD70 | CD70 antigen binding agent |
| Ziralimumab | — | BSG | Basigin inhibitor |
| Zolimomab aritox | — | CD5, 80S Ribosome | T-cell surface glycoprotein CD5 binding agent |
| Anivovetmab | Phase 2 | — | — |
| Tirnovetmab | Phase 1 | — | — |
| Bedinvetmab | — | NGF | Beta-nerve growth factor binding agent |
| Frunevetmab | — | NGF | Beta-nerve growth factor binding agent |
| Lokivetmab | — | IL31 | Interleukin 31 binding agent |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO